CVS Health’s proposed purchase of Aetna will change the way many major U.S. corporations buy health coverage for employees, according to benefit consultants.
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. The deal is expected to close in the first quarter of 2018.
Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.
Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.
Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.
U.S. pharmacy operator CVS Health Corp. made an offer to acquire No. 3 U.S. health insurer Aetna Inc. for more than $200 per share, or over $66 billion, sources said.
U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s via a drug development deal worth more than $200 million with unlisted biotech company Alector.
Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.
Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.